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Abstract
Disseminated candidiasis is the third leading nosocomial blood stream infection in the United States and is often fatal. We
previously showed that disseminated candidiasis was preventable in normal mice by immunization with either a
glycopeptide or a peptide synthetic vaccine, both of which were Candida albicans cell wall derived. A weakness of these
studies is that, unlike humans, mice do not have a C. albicans GI flora and they lack Candida serum antibodies. We examined
the influence of C. albicans GI tract colonization and serum antibodies on mouse vaccination responses to the peptide, Fba,
derived from fructose bisphosphate aldolase which has cytosolic and cell wall distributions in the fungus. We evaluated the
effect of live C. albicans in drinking water and antimicrobial agents on establishment of Candida colonization of the mouse
GI tract. Body mass, C. albicans in feces, and fungal-specific serum antibodies were monitored longitudinally. Unexpectedly,
C. albicans colonization occurred in mice that received only antibiotics in their drinking water, provided that the mice were
housed in the same room as intentionally colonized mice. The fungal strain in unintentionally colonized mice appeared
identical to the strain used for intentional GI-tract colonization. This is the first report of horizontal transmission and
spontaneous C. albicans colonization in mice. Importantly, many Candida-colonized mice developed serum fungal-specific
antibodies. Despite the GI-tract colonization and presence of serum antibodies, the animals made antibodies in response to
the Fba immunogen. This mouse model has potential for elucidating C. albicans horizontal transmission and for exploring
factors that induce host defense against disseminated candidiasis. Furthermore, a combined protracted GI-tract colonization
with Candida and the possibility of serum antibody responses to the presence of the fungus makes this an attractive mouse
model for testing the efficacy of vaccines designed to prevent human disseminated candidiasis.
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Introduction
Disseminated candidiasis is the third leading nosocomial blood
stream infection in the United States [1]. Despite availability of
several drugs that are inhibitory to Candida spp., which cause
disseminated candidiasis, over 40% of treated patients die of this
disease [2,3]. Development of an anti-candidiasis vaccine offers a
preventive approach to reducing the incidence of disease [4,5].
Several groups have been working toward an anti-Candida vaccine.
Some have focused on cell mediated immunity as the mechanism
of protection [6], which is in accordance with the literature [7–8],
whereas we [4,9] and others [5,10,11] have determined that
antibodies specific to certain Candida antigens are protective.
The antibody-mediated protection approach against candidiasis
has been controversial because candidiasis patients and experi-
mental animals with Candida-specific antibodies may not show
evidence of disease resistance. Furthermore, intact cells of
C. albicans, the prevalent specific cause of disseminated candidiasis,
may or may not induce protective antibody responses in
experimental animals [12]. We’ve shown that specific anti-
mannan antibodies are protective if they recognize b-1,2-
mannotriose or –mannobiose moieties of the phosphomannopro-
tein complex, whereas antibodies specific for a-linked mannan of
the same complex are not protective [13]. The important point,
from the standpoint of antibody-mediated protection, is that the
enormous antigenic complexity of the Candida cell [14–18] should
not be expected to reliably induce production of protective
antibodies, as defined by specificity, titer, isotype and effector
function.
Rather than providing the host with a highly complex array of
Candida antigens, a more predictive protective response should be
inducible by a vaccine comprised of a limited number of defined
specific antigens. To that end, we developed a completely synthetic
vaccine consisting of a b-1,2-mannotriose linked via a non-
immunogenic tether to a peptide derived from a protein associated
with cytosolic and cell wall compartments of C. albicans [4].
Antibodies induced to the beta-linked mannotriose equally
recognize both beta-mannotriose and beta-mannobiose [19] and
are protective against disseminated candidiasis. These beta-
oligomannosides are produced by C. albicans and several additional
Candida species [9,20–23]. The peptide chosen for the current
study was designated as Fba and is a 14 amino acid sequence
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This peptide was originally tested for its’ putative T-cell carrier
effect in facilitation of induction of antibody against the beta-
mannotriose. Surprisingly, mice immunized against the manno-
triose-Fba glycoconjugate made antibody against both moieties [4]
and animals immunized against the Fba alone also produced
antibodies against the peptide. Here we employ the peptide alone
as the Candida-specific immunogen, which, as explained below,
allowed us to distinguish host response to Candida colonization of
the GI-tract from immunogen-induced antibody responses.
Our heretofore use of normal mice in protection studies has two
important limitations. First, humans are often colonized with
C. albicans in the GI-tract, while other animals [24] including
normal laboratory mice are not. Second, most humans have a
complex array of polyclonal C. albicans-specific antibodies
circulating in their blood-vascular system, whereas normal mice
do not. These limitations have raised questions as to whether GI
tract colonization with the fungus and/or antibody responses to
prior or present colonization will mitigate a vaccine response [12].
Adult mouse GI-tract colonization with C. albicans sustained for
2–3 weeks has been achieved by a number of investigators [25–31].
In an attempt to study the effects of C. albicans colonization over
several months, we began by following a recently described protocol
[32], and incorporated several modifications. The modified
protocol resulted in a prolonged colonization that lasted over 80
days. The colonization can lead to the appearance of serum
antibodies specific for C. albicans. Surprisingly, mice treated with
oral antibacterial agents were found to be susceptible to horizontal
transmission and GI-tract colonization of the fungus transmitted
from intentionally colonized animals. Furthermore, we showed that
the Candida-colonized mice were still capable of producing
antibodies in response to a peptide vaccine against candidiasis.
For the first time, novel vaccine formulations and delivery systems
acceptable for human use may be tested in mice that have a
protracted C. albicans colonization of the GI tract and anti-fungal
antibodies in their blood. In addition, this animal model may be
useful for studies on host-to-host transmission of the fungus.
Results
Pilot experiment: Evidence for protracted colonization
and antibody production
Ina pilot experimentoffour groupsofthree C57BL/6miceeach,
the variables were fluconazole, cyclophosphamide, no antibiotics
prior to C. albicans ingestion, and gentamicin (Table 1). These
variables were selected as based on the mouse model previously
described [32]. Groups 1 and 2 were treated with antibacterial and
antifungal agents priortofivedaysoforalingestionofliveC.albicans.
In addition, group 2 received an immunosuppressive drug after the
fivedayingestionperiod.Group 3 received onlyantibacterial agents
and group 4 didnot receive antibiotics prior to the five dayperiodof
ingesting C. albicans (Table 1). All mice were immunized with the
Fba peptide vaccine starting on day 51. Mice treated with
antimicrobial agents prior to fungal ingestion appeared stressed by
day 2 of the experiment as indicated by ruffled fur and weight-loss
by some of the mice, but by around day 11 all of the animals except
those that received the cyclophosphamide appeared healthy with
smooth coat and weight increase (Fig. 1). Fecal samples obtained
before and at day 4 of antibiotic treatment were homogenized in
DPBS, plated onto trypticase soy agar containing 5% sheep blood
and incubated aerobically at 37uC for up to 4 days. Homogenized
feces from before and during treatment yielded heavy and no
bacterial growth, respectively. Day 0 (before initiation of antibiotic
therapy) and day 4 homogenized feces yielded no evidence of yeast
colonies, whether or not they were treated with fluconazole, when
plated onto glucose-yeast extract-peptone agar containing chlor-
amphenicol.FollowingingestionofC. albicans duringdays 5–9ofthe
experiment, Candida colonization was maintained throughout the
remainder of the experiment in all groups, but was highest in group
2 animals that were treated three times with cyclophosphamide
every other day starting on day 11. In a previous experiment by
others [32], animals treated similarly to the group 2 animals in our
experiment died by day 7 after cyclophosphamide immunosup-
pression. In our experiment, two mice in group 2 survived 100 days
before becoming moribund and were sacrificed. We do not know
the reason for the protracted survival of immunosuppressed mice in
our experiment, except that in the Koh et al study, C3H/HeN mice
were used as compared to C57BL/6 mice in our study [32].
By day 43 of the experiment, which was 34 days after cessation
of C. albicans in the water, serum antibodies specific for a 2-
mercaptoethanol extract of C. albicans enriched for cell surface
phosphomannoprotein complexes [33] were detected in one
animal in group 1 and all animals in groups 3 and 4, but none
in group 2 animals that received the cyclophosphamide immuno-
suppression treatments (Fig. 1, panel B). Groups 3 and 4
maintained the highest titers as indicated by absorbance of ELISA
readings on a 1:100 dilution of each serum sample. All mice were
vaccinated with the Fba peptide on day 51 and serum antibodies
specific for the Fba were detectable in all mice by day 87, with the
cyclophosphamide-treated animals (group 2) giving the weakest
response as expected (Fig. 1). Since the Fba vaccine induces
antibodies that do not recognize epitopes in the mannan extract
(data not shown), the increase of anti-mannan antibodies at day 65
was presumably due to the continued presence of C. albicans GI
tract colonization. Likewise, as we show below, non-immunized
mice colonized with the fungus do not develop anti-Fba
antibodies, therefore the anti-Fba response was due to the vaccine.
This pilot experiment addressed a large number of variables,
some of which were not adequately controlled. Nonetheless, the
results provided at least preliminary indications that a protracted
C. albicans colonization of the adult mouse GI tract is possible,
colonization may lead to development of serum antibodies that
recognize cell surface epitopes of the fungus and colonized
antibody-producing mice may respond to the Fba vaccine by
making antibodies specific to the Fba peptide.
First follow-up experiment: Initial suggestion of
horizontal transmission of C. albicans
The next experiment was performed using BALB/c mice and
addressed the above variables, except that cyclophosphamide
Table 1. Pilot experiment treatment schedule examining
multiple variables.
Water contents/Day
12345 – 9 1 0 + 11 13 15
Grp
1 p/s/f p/s/f p/s/f p/s/- p/s/Ca p/s/g
2 p/s/f p/s/f p/s/f p/s/- p/s/Ca p/s/g cyclo cyclo cyclo
3 p/s/- p/s/- p/s/- p/s/- p/s/Ca p/s/g
4 -/-/- -/-/- -/-/- -/-/- p/s/Ca p/s/-
p, penicillin; s, streptomycin; f, fluconazole; Ca, C. albicans; g, gentamicin; cyclo,
cyclophosphamide.
doi:10.1371/journal.pone.0022030.t001
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chosen because of its’ extensive use in our previous studies and to
show that mice with different MHC haplotypes behave similarly.
This experiment included more extensive controls, such as
presence or absence of C. albicans in the drinking water (Table 2).
As with the C57BL/6 mice in the pilot experiment described
above, plating of undiluted homogenized feces yielded confluent
growth of bacteria prior to the start of antibiotics, but no growth
by day 4 of antibiotic treatment. Likewise, no evidence of viable
yeast was found in feces prior to initiation of antibiotic treatment.
As in the pilot experiment, C. albicans colonized the GI tract of
BALB/c mice that were treated with antibiotics and received the
fungus in their drinking water on days 5–9 (Fig. 2, groups A, C and
G). Control mice that were not treated with antibiotics did not
develop a sustained Candida flora following ingestion of the fungus
(Fig. 2, group E). Unexpectedly, another control group that was
treated with antibiotics, but not fed the fungus, developed a
protracted fungal colonization (Fig. 2, groups B, D and H). This
result was surprising because (normal) mice not treated with
antibiotic water were highly resistant to prolonged GI-tract
colonization even when C. albicans was added to the drinking
water (Fig. 2, group E). Indeed, this is the first observation on an
apparent spontaneous colonization of the mouse GI tract with
C. albicans. Furthermore, the antibiotic dependency of this result
was confirmed by groups F and I (Fig.2) that did not receive
antibiotics in their water, and they did not have fungi in their stool.
This experiment was thus confounded by spontaneous develop-
ment of GI-tract colonization in groups B, D and H and raised the
question as to the identity and source of the colonizing fungus in
these groups.
Growth on ChromAgar gave presumptive evidence that all
randomly selected colonies from stool samples obtained from
groups B, D and H, were C. albicans. All colonies produced the
same green pigmentation typical of this species growing on this
medium and the pigmentation was identical to that of the
C. albicans strain SC5314 that was fed to the mice (data not shown).
Figure 1. Body mass, GI-tract colonization and appearance of Candida albicans-specific antibodies as a function of time. Mice were
given antibiotics in their water prior to and during ingestion of live C.albicans. Changes in body weight were monitored throughout the experiment,
as was C. albicans colonization as measured by fungal colony forming units (CFU) per gram weight of feces (Panel A). One group was
immunosuppressed (group 2) and all were followed for serum anti-mannan antibody induced as a result of GI-tract colonization. All mice were
immunized and appearance of serum antibody against the vaccine immunogen, Fba, indicated whether they responded to the vaccine (Panel B,
compare day 11 before vaccination to day 87 after vaccination). Groups 1 and 2 received antibacterial agents and fluconazole, but only group 2 was
treated with cyclophosphamide. Group 3 was similar to 1, except that 3 did not receive fluconazole. Group 4 was not pretreated with antimicrobial
agents prior to ingesting C. albicans, and this group was not maintained on gentamicin. Antibody responses were measured by ELISA for a 1:100
dilution of each serum and are expressed as OD490nm. Shown are antibody responses at days 11, 43 and 65 to a mannan fraction (a-mannan), which
occurred as a result of GI-tract colonization, and antibody against Fba peptide, which occurred as a result of Fba vaccination (Panel B). In this
experiment all mice were vaccinated on day 51 and boosted on days 65 and 79.
doi:10.1371/journal.pone.0022030.g001
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amplified multilocus sequence typing (MLST) products of all
randomly selected C. albicans isolates selected from mice that were
either spontaneously or intentionally colonized. This strongly
indicated that spontaneous colonization was due to the C. albicans
strain used for intentional colonization. These results also
suggested that mice that were not intentionally colonized (group
B, D and H, Fig. 2) acquired C. albicans from intentionally-
colonized mice that were housed in the same room. Throughout
the experiment, all mice were kept exclusively in our AAALAC-
certified animal facility complete with HEPA-filtered controlled air
flow. In accordance with policy, each cage contained no more
than five animals. All food, water, water bottles, cages and bedding
were pre-sterilized, each cage was fitted with micro-barrier tops
and the cages were kept in a full ventilation environmental housing
system that provided HEPA filtered air supply and HEPA filtered
exhaust (ACE Micro-Vent Environmental Systems, Allentown
Caging Equipment Co, Allentown, NJ). In addition, all personnel
wore PPE equipment including gloves, sterile gowns, masks,
bonnets and shoe-booties. These approaches made cross contam-
ination unlikely during undisturbed housing of the animals, but
cross contamination was certainly a possibility during cage
cleaning procedures and mouse handling during experimental
procedures. To address the cross-contamination possibility, the
experiment was set-up again, but this time we included housing a
few duplicate groups in an isolated room as described below.
Second follow-up experiment: Solid evidence for
horizontal transmission
To address the Candida source question, the experiment on
BALB/c mice was again set-up as shown in Table 2, but with
duplication of groups B, D and H; the duplicates were housed in
an isolated room in the vivarium and referred to as B’, D’ and H’
(Tables 2 and 3). All other groups were housed in a common room
as in the previous experiment. The mice were provided with
specialized water (Tables 2 and 3), with B’, D’ and H’ in isolation
receiving identical water treatments as in common room groups B,
D and H, respectively. Groups G, H, and H’ were vaccinated with
Fba-dendritic cells intraperitoneally starting with the priming dose
on day 31 of the experiment, boosted with the same 14 days later
and boosted 14 days later subcutaneously with Fba prepared as an
emulsion in CFA. All non-vaccinated mice were given adjuvant
alone subcutaneously as a control at the time of the second booster
for the vaccinated groups (day 59). As in the previous experiment,
facultative anaerobic bacterial growth in fecal specimens was
inhibited by antibiotic treatment and there was no evidence of
yeast in the feces of any mice prior to the start of antibiotic
therapy. The animals were followed for weight changes, Candida
CFU’s in stool, serum antibodies specific for cell wall phospho-
mannoproteins and for Fba. This part of the experiment was
terminated on day 80.
Antibiotic-treated mice showed an initial weight drop during the
first few days as in the previous experiments, but then steadily
gained weight until day 80. As in the previous experiment,
regardless of whether they were fed C. albicans in the drinking
water, all antibiotic-treated mice in the common room developed
a fungal colonization of the GI tract by day 66 of the experiment
(Fig. 3, panel A: groups A, B, C, D, G, and H).
More rigorous measures were taken in this experiment as
compared to the previous experiment to reduce cross-contamina-
tion between the groups during handling of the mice. For example,
personnel who handled the mice in the isolated room did so prior
to entering the common room. In both rooms gloves were changed
between cages, separate weighing vessels were used for each cage
to determine mouse weights and to collect stool specimens. The
stricter precautions in this experiment may have accounted for the
delayed onset of Candida colonization of non-fungal fed animals
that received antibiotics (compare Figs 2 and 3 for groups B, D
and H), but as in the previous experiment colonization of non-
Candida fed antibiotic-treated mice in the common room could not
be prevented.
As in the previous experiment, colonies in stool samples from
groups B, D and H were tested for appearance of growth on
ChromAgar and for strain identity by multilocus sequencing.
Again, ChromAgar growth was green and identical to that of the
SC5314 that was used for intentional colonization. Multilocus
sequencing was extended to include additional primers for strain
comparisons [34], but the results of over 20 randomly-selected
colonies were essentially identical with sequences obtained with
the primers against the SC5314 strain.
The Candida colonization occurring in antibiotic-treated non-
Candida fed mice kept in the common room, lack of colonization in
isolated antibiotic-treated mice and colonization caused by the
same strain in non-Candida fed mice as that in animals intentionally
colonized provide evidence that antibiotic-treated mice are
exquisitely susceptible to host-to-host transmission of the fungus.
The mechanism of host-to-host transmission likely includes fomites
contaminated with C. albicans intentionally colonized mice. Gloves,
bedding aerosols, mouse restrainers used during bleedings and
cross-cage fecal contamination during cage cleaning may well have
played a role in the transmission of the fungus from intentionally
colonized mice to antibiotic treated animals.
Mice that survived the experiment were sacrificed and analyzed
for sites of colonization within the GI tract. Colonization on a per
gram basis was light to non-existent in the esophagus, slightly more
abundant in the stomach and small intestines, but especially high
fungal presence was associated with the cecum and the large
intestine (Fig. 4). These results are similar to those described by
others [27] in short-term experiments on an outbred strain of adult
mice.
As determined in the pilot experiment, prior to immunization,
colonized mice may show the appearance of antibodies specific for
cell phosphomannoprotein complexes in their sera, but not to the
vaccine peptide Fba. In this experiment, anti-phosphomannopro-
tein responses were detected in some of the colonized mice by day
Table 2. Experiment leading to preliminary indications of
horizontal transmission of Candida albicans.
Water contents/Day
12345 – 91 0 +
Grp Fba vac
A 2 p/s/f p/s/f p/s/f p/s/- p/s/Ca p/s/g
B 2 p/s/f p/s/f p/s/f p/s/- p/s/- p/s/g
C 2 p/s/- p/s/- p/s/- p/s/- p/s/Ca p/s/g
D 2 p/s/- p/s/- p/s/- p/s/- p/s/- p/s/g
E 2 -/-/- -/-/- -/-/- -/-/- -/-/Ca -/-/-
F’’normal’’ 2 -/-/- -/-/- -/-/- -/-/- -/-/- -/-/-
G + p/s/- p/s/- p/s/- p/s/- p/s/Ca p/s/g
H + p/s/- p/s/- p/s/- p/s/- p/s/- p/s/g
I’’normal’’ + -/-/- -/-/- -/-/- -/-/- -/-/- -/-/-
F and I’’normal’’ represent the negative and positive normal mouse controls,
respectively.
doi:10.1371/journal.pone.0022030.t002
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5/5 mice) occurred in group G animals that received antibiotics
and were intentionally colonized. Mice in groups A and C were
next in titer and consistency. Only 3 of 15 mice in the antibiotic-
treated animals that became spontaneously colonized (groups B, D
and H) showed the presence of serum antibodies, but this might be
due to the delay in colonization until around 60+ days as
compared to colonization occurring during days 5–9 in mice that
received the fungus in their water. The rules governing whether a
colonized animal will develop serum antibodies are not obvious
and require further investigation.
In mice that received the vaccine starting on day 31 and ending
with the second booster on day 59 (i.e., groups G, H, H’ and I),
antibody specific for the Fba peptide was detectable in their sera
by day 71 (Fig. 6). Anti-Fba responses occurred in all animals in
group G even though all mice in that group were also making
antibody reactive with the phosphomannoprotein complexes from
the cell wall as a result of colonization (Fig. 5).
These data indicate that the Fba vaccine can induce specific
anti-vaccine responses in animals colonized with C. albicans in their
GI tract and have circulating antibodies specific for the fungus
prior to immunization.
Discussion
Characterization of the colonization model
Three independent experiments showed that a protracted
C. albicans GI-tract colonization in adult inbred strains of mice
could be reliably induced. The colonization can be expected to last
at least 80 days, which markedly extends the observation period
reported by others [25–31] thereby providing an opportunity for
long-term experimentation with this model. The extent of
Figure 2. Antibacterial therapy is required for a protracted GI-tract colonization with C. albicans. Mice received oral administration of
various combinations of antimicrobial agents, live C. albicans, and a peptide (Fba) vaccine. Control groups did not receive one or more of the
treatments. All groups that received at least two of the antibacterial agents and were fed C. albicans for a five day period (e.g., groups A, C and G)
developed a protracted GI-tract colonization with the fungus as evidenced by the presence of the fungus in fecal specimens. Antibiotics were
required for the fungal colonization as shown by the presence of C. albicans in the feces of group E only during the five day feeding period.
Surprisingly, antibiotic-treated mice that were not fed C. albicans also became colonized (groups B, D and H). These results suggested the possibility
that antibiotic-treated mice are susceptible to horizontal transmission of the fungus. p=penicillin; s=streptomycin; f=fluconazole; +Ca=C. albicans
in drinking water on days 5–9; +Vac=vaccinated with Fba. Each mouse in each group is represented by an open circle, closed circle or closed triangle.
doi:10.1371/journal.pone.0022030.g002
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but in general the fungal counts were in the range of 2–
8610
7 CFU/g feces. The highest counts occurred several weeks
after feeding of the fungus to C57BL/6 mice that were also treated
with the immunosuppressant cyclophosphamide. As expected, the
cyclophosphamide-treated mice did not respond by making
antibodies to the presence of C. albicans colonization by day 43
(Fig. 1), but a low antibody titer was detectable by day 87 to the
mannan extract (data not shown). Apparently, by this time the
effect of the last cyclophosphamide treatment given on day 15 had
waned, which is supported by the antibody response of the two
survivors of this group to the Fba vaccine that was started on day
51 of the experiment (Fig. 1). The pilot experiment indicated that
it was not essential to treat the animals with antibacterial and
antifungal agents prior to a five day oral feeding with the fungus.
We anticipated that BALB/c mice should behave similarly.
Additional control groups were added and to reduce the number
of variables the immunosuppressant was not pursued in experi-
ments with this mouse strain. BALB/c animals also readily
developed a protracted GI-tract colonization with C. albicans
following a five day period of oral feeding with the fungus. This
colonization was antibiotic-dependent because BALB/c mice that
did not receive antibiotics did not develop prolonged colonization
following oral feeding with the fungus.
The health of all animals appeared normal by around day 11 of
the experiments.In the pilot study,micewereprebled only 2–3 days
prior to the start of the antibiotic-treated water for drinking. In that
study, about 10% of the animals had died by day 5. In subsequent
experiments, prebleeding five or more days before the start of the
experiment resulted in almost 100% survival. We speculate that the
loss of life in the pilot experiment could have been due to
hypovolemia and probable toxic effects due to antibiotic-induced
death of GI-tract microbial flora. The mice were initially reluctant
to drink the antibiotic water, thus dehydration due to lack of
drinking coupled with loss of blood during the prebleeding and the
die-off of intestinal flora, may have been sufficient to cause the early
deaths of a few of the animals. By day 11, however, the animals
regained their weight and continued to thrive thereafter.
The sites of colonization within the GI tract were marked by the
presence of the fungus in highest number in the caecum, followed
by the colon. The stomach and small intestine were relatively light
in fungal burden and the esophagus had barely detectable CFU’s.
This distribution within the GI tract is similar to the findings of
others [27], even though our assessment was done 80–100 days
into the colonization as compared to ,20 days in the cited study.
Although contradictory literature on C. albicans colonization sites
in humans have been reported, several studies show similarities to
results of our studies [35], which provides additional rationale for
the use of the mouse model described in our work for studies on
candidiasis pathogenesis.
Horizontal transmission of the fungus
An unexpected finding occurred when antibiotic-treated mice
that were not intentionally colonized by the oral route, but were
housed in the same room as mice that received a five day oral
feeding of C. albicans, also became colonized. The data strongly
indicate that the transmission was due to the same strain as that
used for intentional feedings. These findings ruled-out the
possibility that another Candida species, such as C. pintolopesia that
may be found in the GI-tract of some mice [36–39], was
responsible for the spontaneous colonization of antibiotic treated
animals. Importantly, antibiotic-treated mice not fed C. albicans,
but kept in an isolated room, did not develop GI-tract
colonization.
Our results allow us to speculate on the mechanism of
horizontal transmission of C. albicans in the common room. First,
we clearly show that the Candida albicans picked-up by the
antibiotic-treated animals is the same strain as that used for
intentional colonization. This result rules-out introduction of a
strain of the fungus from an exogenous source, such as a strain that
might be carried by the animal handlers. This is not surprising
because all animal handlers routinely wear PPE, including gloves,
face masks, bonnets, autoclaved gowns and shoe-booties as
indicated in the Results section. It does not, however, necessarily
rule out the possibility that investigators handling the fungal strains
in the laboratory transmitted the strain when handling the
Table 3. Treatment schedule and results of experiment to address horizontal transmission and antibody responses due to GI-tract
colonization and Fba immunization.
Grp Fba vac Water//+ or 2 Ca Day 66 Day 71 Day 71
Avg(SE) Ca/g feces Avg(SE) anti-man Avg(SE) anti-Fba
A 2 p/s/f//+Ca 1.76610
7(1.8610
5) 0.37(0.15) 0.16(0.02)
B 2 p/s/f//-Ca 2.98610
7(4.76610
5) 0.08(0.01) 0.20(0.03)
B’ 2 p/s/f//-Ca None detected 0.07(0.01) 0.19(0.02)
C 2 p/s/-//+Ca 3.41610
7(5.33610
5) 0.28(0.10) 0.19(0.01)
D 2 p/s/-//-Ca 5.44610
7(6.62610
6) 0.11(0.03) 0.22(0.01)
D’ 2 p/s/-//-Ca None detected 0.08(0.01) 0.23(0.02)
E 2 -/-/-//+Ca 4.02610
4(2.79610
4) 0.08(0.01) 0.25(0.01)
F’’normal’’ 2 -/-/-//-Ca None detected 0.08(0.01) 0.21(0.02)
G + p/s/-//+Ca 4.21610
7(4.58610
6) 0.44(0.11) 0.69(0.03)
H + p/s/-//-Ca 4.64610
7(4.58610
6) 0.13(0.04) 0.83(0.04)
H’ + p/s/-//-Ca None detected 0.12(0.03) 0.86(0.13)
I’’normal’’ + -/-/-//-Ca None detected 0.09(0.01) 0.83(0.02)
Grp designations are similar to Table 2, except B’, D’ and H’ were in an isolated room. Immunization with Fba vaccine commenced on day 31, first booster day 45 and
second booster day 59. All non-vac animals received adjuvant only on day 59.
doi:10.1371/journal.pone.0022030.t003
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appropriate PPE. Second, in the first experiment, which indicated
the possibility of horizontal transmission, a common vessel was
used to immobilize the animals to obtain weights and to collect
stool specimens and gloves were not changed between cages.
Third, in contrast to the above experiment, in the final
experiment, which confirmed horizontal transmission, duplicate
groups of antibiotic-treated mice not intentionally colonized were
housed in an isolated room rather than in the common room
containing intentionally and non-intentionally colonized mice. In
this experiment, strict handling protocols dictated that personnel
always handle animals in isolation before entering the common
room, gloves were always changed between cages and separate
sterile weighing vessels were used for each cage. These measures
resulted again in horizontal transmission of the fungus in the
common room, but colonization did not occur in the isolation
room, which militates against a hypothesis that the fungal strain
was introduced by investigators. However, the colonization was
Figure 3. Confirmation of horizontal transmission of C. albicans in mice treated with antibacterial agents. Antimicrobial-treated mice
not fed C. albicans (groups B, D and H) housed in a common room (Panel A) with other groups of mice intentionally colonized with the fungus (+Ca),
began showing evidence of fungal colonization by day 38 (group H) or after day 52 (groups B and D). Duplicate groups of B, D and H kept in an
isolated room (i.e., groups B’, D’ and H’, respectively) did not show evidence of the fungus in their feces (Panel B). p=penicillin; s=streptomycin;
f=fluconazole; +Ca=C. albicans in drinking water on days 5–9; +Fba=vaccinated with Fba starting on day 31. The various symbols on the curves
represent each animal subject.
doi:10.1371/journal.pone.0022030.g003
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experiment. These findings have led us to conclude that antibiotic-
treated mice are exquisitely sensitive to becoming colonized with
C. albicans. The most likely mode of transmission is fomite
contamination, and possibly aersols of bedding debris, that occurs
while removing the cages from the ventilation environmental
housing system and handling each of the animals during cage
cleaning and while performing procedures to obtain animal
weights and stool collections.
Since normal laboratory mice are not naturally colonized with
C. albicans, and unusual measures are necessary to induce GI-tract
colonization in the laboratory mouse [40], it was not surprising in
our studies that non-antibiotic treated animals were highly
resistant to Candida colonization even when intentionally fed the
fungus (e.g., Fig. 2, group E). Furthermore, none of the non-
antibiotic-treated animals developed colonization as a result of
exposure to colonized mice in the common room (Fig. 2, groups F
and I). The latter animals would be considered as normal
laboratory mice, which have not been reported to being
susceptible to horizontal transmission of the fungus. Our finding
that antibiotic-treated mice are apparently exquisitely susceptible
to horizontal transmission of C. albicans can be exploited in studies
on host to host transmission of C. albicans. Indirect and direct
human-to-human transmission of this and other Candida species is
Figure 4. GI-tract colonization was especially profound in the cecum and large intestine. Mice that survived the experiment (Fig. 3), were
sacrificed by CO2 asphyxiation, the GI-tract was sectioned into major components, homogenized and plated for fungal burden (C. albicans CFU/gram
tissue). Each mouse per group that survived for processing are noted on the X-axis.
doi:10.1371/journal.pone.0022030.g004
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22030Figure 5. C. albicans colonization of mice may result in appearance of serum antibodies specific for a mannan extract of the fungus.
By day 71, serum antibody was especially obvious in mice that were treated with antimicrobial agents and received C. albicans in their drinking water
(i.e., groups A, C and G;see Table 3). Only one mouse from each of two groups that became colonized later as a result of horizontal transmission had
evidence of serum antibody (groups B and D). Note that the sera from groups H and H’ were not properly marked for identification of H or H’ and
were, thus, both designated as H* and H*. The positive control (+ctrl) for the ELISA was monoclonal antibody B6.1, which is specific for a mannan
component in the C. albicans cell wall. The negative control (-ctrl) contained all of the ELISA reagents except for primary antibody, which was omitted.
doi:10.1371/journal.pone.0022030.g005
Figure 6. Vaccination induced appearance of serum antibodies regardless of colonization status. All mice immunized with the Fba
vaccine (groups G, H, H’ and I) developed serum antibodies against the Fba immunogen. Note that the sera from groups H and H’ were not properly
marked for identification of H or H’ and were, thus, both designated as H* and H*.
doi:10.1371/journal.pone.0022030.g006
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transmission are not clear. Use of this animal model should allow
experimentation to address both points.
Development of serum antibodies in response to
Candida colonization and vaccination
Mice may develop serum antibodies specific for cell surface
antigens on the fungal cell wall in response to the colonization.
Rules for predicting which of the animals would make a polyclonal
antibody response were not obvious. For example, in the last
experiment (Table 3 and Fig. 5), in two groups of mice
intentionally colonized, 3/5 mice in group A developed serum
antibodies, whereas in 5/5 mice in group G developed antibodies.
These results show that mice may respond to the presence of
C. albicans colonization by producing antibodies reactive with the
fungal cell surface. Although not all colonized mice developed
serum antibodies due to the presence of the fungus in their GI
tract, a sufficient number of mice do develop antibodies which
makes this model useful for determining whether animals making
preformed antibodies against the fungus are capable of responding
to a vaccine against candidiasis.
The Fba vaccine was chosen for these studies because we could
readily distinguish between peptide vaccine-induced serum
antibodies from antibodies that developed in response to the GI-
tract colonization with the fungus. All mice that received the Fba
vaccine responded by making specific antibodies against the
peptide. The anti-Fba response occurred due to the vaccine rather
than the colonization. Anti-Fba antibodies were not detected in
sera of colonized animals prior to vaccination and at no time did
colonized non-vaccinated animals make a detectable anti-Fba
response. These results show that Candida-colonized mice, some of
which with serum antibodies, are capable of responding to a
vaccine against candidiasis. For purposes of human vaccination
this is an important finding, because most humans are at least
transiently colonized with the fungus in their GI tract and they
have anti-Candida antibodies in their serum. In future experiments
we will determine whether such animals respond to more complex
synthetic glycopeptide conjugate vaccines already described [4,44]
and those that are in development in our lab, as well as improved
delivery systems more suitable for human use. These future
experiments will allow us not only to assess responsiveness of these
mice to improved vaccine designs, but also whether vaccination
affects GI-tract colonization with the fungus and how well
vaccinated mice are protected against a live challenge with
C. albicans and other Candida species.
In summary, adult mice can develop a chronic C. albicans GI-
tract colonization of several months duration provided that their
normal bacterial population is suppressed. Mice with a suppressed
bacterial flora are exquisitely susceptible to acquiring C. albicans
colonization by horizontal transfer of the fungus. Intentionally
colonized animals and animals that become colonized by
horizontal transmission may develop serum antibodies against
C. albicans cell surface epitopes. Regardless of colonization and
serum antibodies, however, all animals can develop a robust
antibody response to a specific anti-C. albicans vaccine. We surmise
that humans would be expected to respond to a vaccine against
candidiasis even though they are colonized with C. albicans and
have serum antibodies against the fungus prior to immunization.
Materials and Methods
Ethical Handling of Animals
All experiments involving mice were detailed and approved
(protocol #120) by the Institutional Animal Care and Use
Committee (IACUC) of the Research Institute for Children prior
to performing any of the experiments. In accordance with IACUC
policies, mice were housed exclusively in an AAALAC-certified
facility. Details of experimental conditions and handling of animals
are given in the appropriate Results section. All animals were
sacrificed by CO2 asphyxiation when they became moribund as
defined by a combination of ruffled fur, hunched back and dulled
response to stimuli, such as finger probing. At the completion of all
experiments, survivors were sacrificed by CO2 overdose in
accordance with IACUC policy.
Reagents
Penicillin G, streptomycin sulfate and gentamicin sulfate were
obtained from Sigma Chem. Co., fluconazole was from LKT
Labs, Inc. and all were supplied as a dry salt or powder. The
preparations of each were penicillin G at 1.51 mg/mL, strepto-
mycin sulfate at 2.02 mg/mL, fluconazole at 0.25 mg/mL and
gentamicin at 0.2 mg/mL in autoclaved tap water and filter-
sterilized (0.2 mm porosity filter) into oven-baked bottles. The
various combinations given to the animals are indicated in
Tables 1, 2, 3. Antibiotic-containing water was made fresh every
seven days.
The fourteen amino acid residue, Fba, used to pulse dendritic
cells in vitro and vaccinate the mice was obtained as a 95% pure
synthetic product from GenScript as before [4]. A multiple
antigenic peptide (MAP) on a lysine backbone to which multiple
Fba moieties were covalently linked to the a- and e-amino
functional groups of lysine was obtained from GenScript. The
MAP-Fba conjugate was used to coat wells for ELISA detection of
antibody against the Fba as described below.
Candida albicans
Strain SC3514 (ATCC MYA-2876) was the colonization strain,
which was supplied to mice in their drinking water. The strain was
retrieved 5–7 days before use in experiments from a water stock by
aseptically placing a loopful into glucose (2%)-yeast extract (0.3%)-
peptone (1%) (GYEP) broth, incubating under rotation (180 rpm)
at 37uC for 18–24 h, transferring to fresh broth for another
incubation, and continuing in this fashion for a minimum of three,
but not more than 5 transfers before use. This method resulted in
over 99% viable yeast forms that had a hydrophilic cell surface as
previously described [45]. On the day of use, the cultures were
examined microscopically to confirm yeast form growth and to
check for bacterial contamination. The cultures were also plated
onto GYEP agar plates and incubated for up to 4 days to confirm
non-contamination. Yeast forms were harvested aseptically by
centrifugation, washed 3 times in sterile tap water, counted by use
of a hemocytometer and appropriately diluted into sterile drinking
water containing penicillin and streptomycin to give 10
7 SC3514
viable yeast/ml drinking water.
Animals, blood collections and stool specimens
C57BL/6 and BALB/c female mice, 2–3 months, were
obtained as 35 day old animals from Harlan Labs, Charles River
Labs or the Jackson Laboratory. The basic strategy for GI-tract
colonization of the mice with C. albicans was done as described by
others [32], but with modifications as indicated in Tables 1 and 2.
In a pilot experiment on C57BL/6 mice, animals in one group
were rendered immunocompromised by giving intraperitoneal
injections of a filter-sterilized solution of cyclophosphamide
monohydrate (Fluka, Sigma-Aldrich) prepared in DPBS to provide
a drug dose of 150 mg/kg on days 10, 12 and 14 of the
experiment. Mice that received C. albicans in their drinking water
were given water containing penicillin/streptomycin along with
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animals that received the Fba vaccine were given intraperitoneally
a priming and first booster dose in the form of Fba-pulsed
dendritic cells and a second booster subcutaneously as Fba
emulsified in complete Freund adjuvant (CFA) (Imject Freund’s
Complete Adjuvant, Thermo Scientific) as previously described
[4]. All non-vaccinated animals were given CFA alone as a control
for an adjuvant effect. Prior to the experiments, a small sample
(,200 ml) of blood was taken by cheek puncture from each animal,
and again at various time points throughout the observation
period to monitor for the presence of antibodies specific for
mannan and Fba by ELISA as previously described [4,9,46].
Animal weights and stool specimens were obtained at specified
times throughout the experiments. Stool specimens taken at
various times were weighed, stored up to 2 weeks at 220uC,
thawed and homogenized in sterile DPBS, appropriately diluted
and plated for C. albicans colony forming units (CFU) on glucose
(2%)-yeast extract (0.3%)-peptone (1%) containing 50 mg/ml
chloramphenicol (Sigma). The storage of stools in the freezer
was done for logistical purposes after we determined that similar
CFU’s were obtained from stools frozen for 24 h or up to two
weeks. At specified times before and during antibiotic treatment,
stool specimens were also processed to determine the presence of
facultative anaerobic bacterial populations. Homogenates were
plated onto trypticase soy agar containing 5% sheep blood (TSA II
5% SB, BBL) at 37uC. All plates were incubated for up to 4 days
for evidence of bacterial growth. Fungal CFU’s per gram fecal
material were calculated, but bacterial growth was observed only
for heavy growth, slight growth or no growth.
Identification of C. albicans from the GI-tract
Several colonies from plated stool homogenates were randomly
selected from various groups of colonized mice. Typical convex
cream-colored colonies, 1–2 mm diameter Candida-like colonies
developed from stool specimens and from all kidney homogenates
by 24 h incubation of the plates at 37uC, but some specimens
yielded also very small colonies (,1 mm diameter). However, all
showed typical budding yeast cells with occasional pseudohyphal
forms under microscopic exam. The colonial types and micro-
scopic appearance were identical to that of strain SC5314 used for
oral feedings. The various selected colonies and strain SC5314
were plated onto ChromAgar for comparison of pigment
development. Multilocus sequence typing (MLST) was used for
species and strain identifications/comparisons. The first analysis
was done by use of primers from six selected housekeeping genes
[47,48] to produce PCR products from purified DNA from each
isolate, the products of which were sequenced (Davis Sequencing).
Subsequently two additional genes were added to the analysis as
described [49]. The various PCR-amplified MLST products from
each selected colony were compared by aligning the sequences
using Sequencher (GeneCodes Corp., Ann Arbor, MI) and visual
inspection of sequence identity.
Detection of serum antibodies
ELISA was used to detect antibodies against cell surface
mannan determinants and against the peptide, Fba, of C. albicans.
For ELISA detection of antibodies primarily against mannan
determinants, an extract of whole yeast form cells enriched for
phosphomannoprotein complexes was obtained by treatment of
the cells with 0.3 M 2-mercaptoethanol. We termed this the 2-ME
extract and have characterized and used the 2-ME extract in
ELISA assays numerous times [4,9,46,50–52]. In brief, ELISA
titers were obtained by coating polystyrene 96 flat bottom wells
with the extract, washing the wells with Dulbecco’s phosphate
buffered saline (DPBS, Sigma) containing bovine serum albumin
(Sigma), blocking by addition of 200 ml/well of DPBS containing
1% BSA, adding mouse serum samples starting at 1:100 dilution in
DPBS-BSA, incubating and washing with DPBS-BSA, adding
secondary antibody (goat anti-mouse Ig-horse radish peroxidase,
Sigma), washing with DPBS-BSA, adding 100 ml/well of substrate
(o-phenylenediamine, Sigma), incubating for 10–20 min at 22–
23uC, stopping the reaction by addition of acid and reading the
OD of each well at 492 nm. Usually end-point titering was not
done, but, rather the OD readings on various days were adjusted
to results for a 1:100 dilution of serum samples normalized to an
internal control consisting of a known concentration of monoclo-
nal antibody B6.1 specific for beta-linked oligomannosides of
C. albicans [46].
To detect antibodies specific for the Fba peptide, wells were
coated with the synthetic MAP-Fba conjugate (10 mg/mL)
overnight 4 C, washed 2X PBS (0.01 M PB, 0.15 M NaCl,
pH 7.4), blocked with 1% BSA in PBS, addition to wells of 100 mL
of a 1:100 of each antiserum (diluted in PBS), washed in PBS-
0.05% Tween 20 3-5x, addition of secondary antibody (goat anti-
mouse whole Ig-HRPO, Sigma), washings and addition of
substrate, stop reagent and OD reading as above.
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